Covid19 Clinical Trial
— CAREOfficial title:
A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx
For caregivers in the Bronx, the pandemic has caused unprecedented psychological distress; in addition to combating social determinants of health (SDOH), these families now face greater financial insecurity and challenges related to their school-aged children. Furthermore, social distancing requirements and limited telehealth resources for Bronx families have posed greater barriers to healthcare. Such parental distress contributes to heightened risk of transgenerational cycles of psychological stress, trauma and maltreatment. The social and economic impacts of the COVID-19 pandemic have had significant consequences for family well-being, putting parents at higher risk of experiencing distress and potentially impairing their ability to provide supportive care to their children. Although children may be less susceptible to the most damaging physical consequences of COVID-19, there are growing concerns regarding the short-and long-term impacts of pandemic-related stressors on children. The marked upheaval of family life over an extended period may make children vulnerable to mental health consequences associated with the public health crisis and infection mitigation efforts. School and childcare closures, unstable financial circumstances, social isolation and lack of support have a disproportionate, cumulative impact on parents and may undermine their capacities to provide support for their children. Importantly, a large body of evidence suggests that parental stress during times of disasters induces psychopathologies in family members including children. Further, high anxiety and depressive symptoms in parents during the pandemic have been associated with higher child abuse potential, whereas greater parental support was associated with lower perceived stress and child abuse potential. In addition to psychological impacts, stress associated with caregiving can interfere with parents' ability to maintain their own health. This multimodal study addresses key strategies to mitigate the psychological and health impact of COVID-19 in parents.
Status | Recruiting |
Enrollment | 360 |
Est. completion date | March 31, 2026 |
Est. primary completion date | March 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - All participants will be primary caregivers who present with moderate level of stress by meeting a severity score of = 14 on the Perceived Stress Scale (PSS22). - Investigators will allow primary caregivers (e.g., grandmothers and aunts) as it is common in our patient population. - Clinical cohorts will be active patients in the psychiatric and rheumatology clinics in Montefiore Medical Center (MMC). - Frontline health care providers will be those who are required to work on site at Montefiore Medical Center (MMC). Exclusion Criteria: - Serious psychiatric or substance use difficulty that, in the judgement of the PI, would preclude meaningful participation in a parent intervention. - Active child abuse/maltreatment cases. - Neurocognitive conditions that may prevent participants from accessing telehealth services. - Primary language other than Spanish or English. - Utilized a smartphone health platform similar to the Valera app. |
Country | Name | City | State |
---|---|---|---|
United States | PRIME | Bronx | New York |
Lead Sponsor | Collaborator |
---|---|
Albert Einstein College of Medicine | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Multidimensional Scale of Perceived Social Support | MPSS | week 0 | |
Other | Multidimensional Scale of Perceived Social Support | MPSS change | week 24 | |
Other | Youth Outcome Questionnaire | YOQ | week 0 | |
Other | Youth Outcome Questionnaire | YOQ change | week 24 | |
Other | COVID Impact Scale | COVID Impact Scale | week 0 | |
Other | COVID Impact Scale | COVID Impact Scale change | week 12 | |
Other | COVID Impact Scale | COVID Impact Scale change | week 24 | |
Other | Kansas Parental Satisfaction Scale | KPSS | week 0 | |
Other | Kansas Parental Satisfaction Scale | KPSS change | week 6 | |
Other | Kansas Parental Satisfaction Scale | KPSS change | week 12 | |
Other | Kansas Parental Satisfaction Scale | KPSS change | week 24 | |
Other | Family Assessment Device-General Functioning Scale | FAD | week 0 | |
Other | Family Assessment Device-General Functioning Scale | FAD change | week 12 | |
Other | Family Assessment Device-General Functioning Scale | FAD change | week 24 | |
Other | Life Events Checklist | LEC | week 0 | |
Other | Life Events Checklist | LEC change | week 12 | |
Other | Life Events Checklist | LEC change | week 24 | |
Other | Health Related Quality of Life | Caregiver Quality of Life | week 0 | |
Other | Health Related Quality of Life | Caregiver Quality of Life change | week 24 | |
Other | PC-PTSD COVID | PC-PTSD COVID | week 0 | |
Other | PC-PTSD COVID | PC-PTSD COVID change | week 24 | |
Other | RaLES-B | Discrimination | week 0 | |
Other | Multidimensional assessment of emotion regulation and dysregulation | DERS-18 | week 0 | |
Other | Multidimensional assessment of emotion regulation and dysregulation | DERS-18 change | week 12 | |
Other | Multidimensional assessment of emotion regulation and dysregulation | DERS-18 change | week 24 | |
Other | Multidimensional Scale Of Perceived Social Support | MPSS change | week 12 | |
Other | PROMIS EARLY CHILDHOOD | PROMIS EARLY CHILDHOOD | week 0 | |
Other | PROMIS EARLY CHILDHOOD | PROMIS EARLY CHILDHOOD change | week 24 | |
Other | PROMIS Parent Proxy Scale | PROMIS Parent Proxy Scale | week 0 | |
Other | PROMIS Parent Proxy Scale | PROMIS Parent Proxy Scale change | week 24 | |
Other | Philadelphia ACE | Philadelphia ACE | week 0 | |
Other | Multidimensional Assessment of Parenting Scale (MAPS) | (MAPS) | week 0 | |
Other | Multidimensional Assessment of Parenting Scale (MAPS) | (MAPS) change | week 12 | |
Other | Multidimensional Assessment of Parenting Scale (MAPS) | (MAPS) change | week 24 | |
Other | Drug Abuse Screening Test | DAST | week 0 | |
Other | Drug Abuse Screening Test | DAST change | week 12 | |
Other | Drug Abuse Screening Test | DAST change | week 24 | |
Other | Alcohol Use Disorders Identification Test (Audit C) | Audit C | week 0 | |
Other | Alcohol Use Disorders Identification Test (Audit C) | Audit C change | week 12 | |
Other | Alcohol Use Disorders Identification Test (Audit C) | Audit C change | week 24 | |
Other | Treatment and Health Behavior Questionnaire | Treatment and Health Behavior Questionnaire | week 0 | |
Other | Treatment and Health Behavior Questionnaire | Treatment and Health Behavior Questionnaire | week 6 | |
Other | Treatment and Health Behavior Questionnaire | Treatment and Health Behavior Questionnaire | week 12 | |
Other | Treatment and Health Behavior Questionnaire | Treatment and Health Behavior Questionnaire | week 24 | |
Primary | Perceived Stress | Perceived Stress Questionnaire | week 0 | |
Primary | Perceived Stress | Perceived Stress Questionnaire Change | weeks 6 | |
Primary | Perceived Stress | Perceived Stress Questionnaire Change | week 12 | |
Primary | Perceived Stress | Perceived Stress Questionnaire Change | week 24 | |
Secondary | Parental Reflective Functioning Questionnaire- Child | Parental Reflective Functioning Questionnaire | week 0 | |
Secondary | Parental Reflective Functioning Questionnaire-Child | Parental Reflective Functioning Questionnaire Change | week 6 | |
Secondary | Parental Reflective Functioning Questionnaire-Child | Parental Reflective Functioning Questionnaire Change | week 12 | |
Secondary | Parental Reflective Functioning Questionnaire- Child | Parental Reflective Functioning Questionnaire Change | week 24 | |
Secondary | Parent Reflective Functioning Questionnaire-Adolescent | Parental Reflective Functioning Questionnaire | week 0 | |
Secondary | Parent Reflective Functioning Questionnaire-Adolescent | Parental Reflective Functioning Questionnaire change | week 6 | |
Secondary | Parent Reflective Functioning Questionnaire-Adolescent | Parental Reflective Functioning Questionnaire change | week 12 | |
Secondary | Parent Reflective Functioning Questionnaire-Adolescent | Parental Reflective Functioning Questionnaire change | week 24 | |
Secondary | Five Minute Speech Sample | FMSS | week 0 | |
Secondary | Five Minute Speech Sample | FMSS Change | week 6 | |
Secondary | Five Minute Speech Sample | FMSS Change | week 12 | |
Secondary | Five Minute Speech Sample | FMSS Change | week 24 | |
Secondary | Beck Depression Index | BDI | week 0 | |
Secondary | Beck Depression Index | BDI change | week 6 | |
Secondary | Beck Depression Index | BDI change | week 12 | |
Secondary | Beck Depression Index | BDI change | week 24 | |
Secondary | Beck Anxiety Index | BAI Change | week 0 | |
Secondary | Beck Anxiety Index | BAI Change | week 6 | |
Secondary | Beck Anxiety Index | BAI Change | week 12 | |
Secondary | Beck Anxiety Index | BAI Change | week 24 | |
Secondary | Beck Suicide Scale Inventory | BSSI | week 0 | |
Secondary | Beck Suicide Scale Inventory | BSSI Change | week 6 | |
Secondary | Beck Suicide Scale Inventory | BSSI Change | week 12 | |
Secondary | Beck Suicide Scale Inventory | BSSI Change | week 24 | |
Secondary | Parent Stress Index | PSI-4 | week 0 | |
Secondary | Parent Stress Index | PSI-4 change | week 12 | |
Secondary | Parent Stress Index | PSI-4 change | week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |